Get the Stockscreener App
4.04
7.29%
-0.35
Nls Pharmaceutics Ltd stock is traded at $4.04, with a volume of 195.20K.
It is down -7.29% in the last 24 hours and down -16.94% over the past month.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
See More
Previous Close:
$4.39
Open:
$4.15
24h Volume:
195.20K
Relative Volume:
1.00
Market Cap:
$15.66M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
-4.8095
EPS:
-0.84
Net Cash Flow:
$-13.51M
1W Performance:
-1.45%
1M Performance:
-16.94%
6M Performance:
-26.27%
1Y Performance:
-84.11%
1-Day Range:
$3.86
$4.215
1-Week Range:
$3.5101
$4.74
52-Week Range:
$3.5101
$29.08
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Nls Pharmaceutics Ltd Stock (NLSP) Latest News
What's Going On With NLS Pharmaceutics Shares Monday? - Benzinga
NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com
NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com UK
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - StreetInsider.com
NLS Pharmaceutics Achieves Nasdaq Compliance Milestone - TipRanks
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - AccessWire
NLS Pharmaceutics Strikes Debt Forgiveness Deal - TipRanks
NLS Pharmaceutics’ $3.2 Million Common Share Offering - Global Legal Chronicle
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - AccessWire
NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges - Yahoo Finance
(NLSP) Technical Pivots with Risk Controls - Stock Traders Daily
NLS Pharmaceutics Boosts Financial Standing with Key Moves - TipRanks
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - Yahoo Finance
NLS Pharmaceutics Regains Nasdaq Compliance - TipRanks
NLS Pharmaceutics Launches New Share Purchase Warrant - TipRanks
NLS Pharmaceutics AG announced that it expects to receive $7.2 million in funding - Marketscreener.com
NLS Pharmaceutics AG announced that it expects to receive $3.201614 million in funding - Marketscreener.com
NLS Pharmaceutics Shareholders Approve Agenda - TipRanks
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise - Marketscreener.com
NLS Pharmaceutics Receives Nasdaq Compliance Extension - TipRanks
NLSP stock touches 52-week high of $4.61 amid market fluctuations - Investing.com
NLS Pharmaceutics announces 1-for-40 reverse stock split - Investing.com
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - AccessWire
A year in review: NLS Pharmaceutics Ltd (NLSP)’s performance in the last year - US Post News
Market Highlights: NLS Pharmaceutics Ltd (NLSP) Ends on a Low Note at 0.14 - The Dwinnex
NLSP: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
NLS Pharmaceutics Shareholders Approve Key Measures - TipRanks
NLS Pharmaceutics Adjusts Warrants Terms - TipRanks
NLS Pharmaceutics Plans Capital Increase and Debt Restructuring - TipRanks
Investor’s Toolkit: Key Ratios for Assessing NLS Pharmaceutics Ltd (NLSP)’s Performance - The Dwinnex
What was NLS Pharmaceutics Ltd (NLSP)’s performance in the last session? - US Post News
NLSP’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Market Update: NLS Pharmaceutics Ltd (NLSP) Sees Negative Movement, Closing at 0.16 - The Dwinnex
NLS Pharmaceutics Prepares for Share Consolidation - TipRanks
A stock that deserves closer examination: NLS Pharmaceutics Ltd (NLSP) - US Post News
NLS Pharmaceutics (NASDAQ:NLSP) Trading 4.3% Higher - Defense World
NLS Pharmaceutics Gains PwC’s Endorsement - TipRanks
NLS Pharmaceutics to Merge with Cell Therapy Developer Kadimastem - Sleep Review
NLS Pharmaceutics Announces CFO Departure Amidst Merger Plans - TipRanks
It is Poised to be a Bull Market for NLS Pharmaceutics Ltd (NLSP) - SETE News
NLS Pharmaceutics Ltd (NLSP) stock analysis: A simple moving average approach - US Post News
Views of Wall Street’s Leading Experts on NLS Pharmaceutics Ltd - SETE News
Quarterly Snapshot: Quick and Current Ratios for NLS Pharmaceutics Ltd (NLSP) - The Dwinnex
Daily Market Movement: NLS Pharmaceutics Ltd (NLSP) Sees a -9.34 Decrease, Closing at 0.22 - The Dwinnex
NLS Pharmaceutics Ltd [NLSP] Stock trading around $0.23 per share: What’s Next? - The DBT News
NLS Pharmaceutics to merge with Kadimastem in stock deal By Investing.com - Investing.com Nigeria
NLS Pharmaceutics to merge with Kadimastem in stock deal - Investing.com India
NLSP’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
NLSP Stock: NLS Pharmaceutics A Beacon of Hope in CNS Disorder Treatment - All Finance Times
Nls Pharmaceutics Ltd Stock (NLSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):